The historical rank and industry rank for Integragen's Days Payable or its related term are showing as below:
XPAR:ALINT'
s Days Payable Range Over the Past 10 Years
Min: 52.76 Med: 87.09 Max: 1632.36
Current: 1632.36
During the past 13 years, Integragen's highest Days Payable was 1632.36. The lowest was 52.76. And the median was 87.09.
XPAR:ALINT's Days Payable is ranked better than 89.22% of 705
companies
in the Biotechnology industry
Industry Median: 113.36
vs XPAR:ALINT: 1632.36
Integragen's Days Payable
declined
from Jun. 2024 (69.63) to Jun. 2025 (0.00).
It may suggest that Integragenaccelerated paying its suppliers.
Integragen Days Payable Related Terms
Integragen Days Payable Historical Data
* Premium members only.
The historical data trend for Integragen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALINT vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Integragen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integragen Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Integragen's Days Payable distribution charts can be found below:
* The bar in red indicates where Integragen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Integragen's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integragen (XPAR:ALINT) has a Days Payable of 0.00 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integragen and its competitors. Over the past decade, Integragen's Days Payable has ranged from 52.76 to 1,632.36. According to the industry distribution chart, Integragen ranks #76 out of 705 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Integragen's Days Payable too high?
Integragen's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 52.76 to a high of 1,632.36. Based on the distribution chart, Integragen ranks #76 out of 705 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Integragen has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integragen's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Integragen ranks #76 out of 705 companies for Days Payable. This places Integragen in the top 11% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.36. Historically, Integragen's own Days Payable has ranged from 52.76 to 1,632.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Integragen and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integragen's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integragen stock overvalued right now?
Based on GuruFocus' analysis, Integragen (XPAR:ALINT) is currently considered Possible Value Trap. The stock's GF Value™ is €0.42, compared to a current price of €0.19 — trading 55.7% below its estimated fair value. The current Days Payable is 0.00. Integragen's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Integragen (XPAR:ALINT), the current Days Payable is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integragen (XPAR:ALINT) Overvalued in 2026?
Based on GuruFocus' analysis, Integragen stock appears to be undervalued.
The current stock price of €0.19 is trading 55.7% below its estimated GF Value™ of €0.42.
GuruFocus considers Integragen to be Possible Value Trap.
Key valuation signals for XPAR:ALINT:
Days Payable: 0.00
GF Value™: €0.42 vs. price of €0.19 (55.7% below fair value)
No single metric tells the full story. See the XPAR:ALINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integragen is engaged in the development of genetic biomarkers. It offers genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, as well as genomic research tools and solutions to microbiologic researchers.
29GF Score
Get the complete analysis for XPAR:ALINT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALINT has been successfully added to your 
